CXR

Blackford and Rayscape Announce Commercial Partnership to Bring Pulmonary Analysis Software to Healthcare Providers

Retrieved on: 
Thursday, January 4, 2024

EDINBURGH, Scotland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Blackford, the pioneering strategic AI platform and solutions provider, and Rayscape today announced a commercial partnership to bring the Rayscape CXR and Rayscape Lung CT solutions to healthcare professionals.

Key Points: 
  • EDINBURGH, Scotland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Blackford, the pioneering strategic AI platform and solutions provider, and Rayscape today announced a commercial partnership to bring the Rayscape CXR and Rayscape Lung CT solutions to healthcare professionals.
  • Blackford provides healthcare professionals access to an extensive portfolio of more than 115 medical AI solutions designed to drive clinical efficiency and improve patient outcomes.
  • By integrating Rayscape’s advanced technology into the Blackford Platform, Blackford can offer healthcare providers powerful tools for detection of multiple pathologies on chest X-rays and nodules detection, analysis and comparison on lung CT scans.
  • “By integrating our Rayscape CXR and Rayscape Lung CT solutions with Blackford's advanced enterprise AI platform, we are not only enhancing diagnostic capabilities but also revolutionizing the way healthcare providers approach chest X-ray analysis and lung cancer detection.

VinBrain to Launch AI-centric Solutions to Save Lives and Advance Precision Care at RSNA 2023

Retrieved on: 
Monday, December 4, 2023

Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.

Key Points: 
  • Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.
  • Expediting interoperability and streamlining, DrAid Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care.
  • Dr. Michael C. Muelly, medical partner of VinBrain shared his point of view about clinical practices and values of the solutions during product launch at RSNA 2023.
  • At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid for Tuberculosis Screening (CXR Screening).

Bering Secures FDA Clearance for AI-Based Chest X-Ray Triage Solution

Retrieved on: 
Wednesday, December 6, 2023

FDA 510(k) clearance for AI Radiology software product, targeting emergency cases found on chest X-Rays.

Key Points: 
  • FDA 510(k) clearance for AI Radiology software product, targeting emergency cases found on chest X-Rays.
  • Bering to accelerate business in the US market, leveraging new and existing partnerships
    LONDON, Dec. 6, 2023 /PRNewswire/ -- Bering Limited, a London-based medical AI company, today announced it received US Food and Drug Administration (FDA) 510(k) clearance for its AI-powered chest X-Ray triage solution, 'BraveCX'.
  • With the FDA clearance, the company is now able to commercially provide the AI solution to medical professionals and healthcare institutions in the US.
  • FDA clearance means BraveCX prioritises patient safety, whilst still delivering the most advanced Risk Stratification algorithms where they are needed the most."

Virtual Reality Market 2023-2027 | The use of virtual reality in training and simulation for aerospace and defense is the market trend- Technavio

Retrieved on: 
Sunday, November 5, 2023

NEW YORK, Nov. 4, 2023 /PRNewswire/ -- The virtual reality market is categorized by Technavio as a subsegment of the application software market.

Key Points: 
  • NEW YORK, Nov. 4, 2023 /PRNewswire/ -- The virtual reality market is categorized by Technavio as a subsegment of the application software market.
  • An important trend in the market for virtual reality is the use of virtual reality in training and simulation for aerospace and defense.
  • Head-mounted display (HMD) adoption in the gaming and entertainment industries is one of the factors driving the market for virtual reality market.
  • Technological advancements in the virtual reality hardware market are projected to improve user acceptance of virtual reality goods.

CXR-AID, Powered by Lunit, Nets Japan Nod for Reimbursement, Accelerating Market Expansion Opportunities

Retrieved on: 
Monday, June 26, 2023

SEOUL, South Korea, June 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of cancer diagnostics solutions, today announced that CXR-AID, FujiFilm's AI solution for chest X-ray analysis, powered by Lunit INSIGHT CXR, has been officially included as an eligible solution for health insurance reimbursement in Japan.

Key Points: 
  • MHLW added the new Class 3 condition for hospitals utilizing AI image diagnostics software and fulfilling specific facility and safety criteria.
  • This significantly boosts Lunit and FujiFilm's expansion in the Japanese market and creates new growth prospects in the field of AI image diagnostics.
  • Its exceptional diagnostic performance led to the approval of the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in 2021.
  • The market expansion of CXR-AID in Japan is further bolstered by FujiFilm's widespread presence, with its screening devices and solutions already being utilized by over 25,000 medical institutions nationwide.

Annalise.ai Builds Momentum in U.S. Market with Seven Additional FDA-Cleared Findings for Imaging Triage and Notification

Retrieved on: 
Wednesday, April 12, 2023

SYDNEY, April 12, 2023 /PRNewswire/ -- Annalise.ai, the global radiology AI company, announced today that it has received FDA 510(k) clearances covering an additional seven findings as part of the company's innovative AI-assisted triage and notification (CADt) solutions. The clearances, including a suite of time-sensitive stroke findings and an expansion of findings for chest X-ray, build on Annalise's momentum and growth strategy in the U.S. market.

Key Points: 
  • Annalise.ai has received new 510(k) FDA clearances for seven additional time-critical findings in its chest X-ray (CXR) and non-contrast head CT triage and notification portfolio.
  • The latest 510(k) FDA clearances build on Annalise.ai's momentum for expanding into the U.S. market, bringing the total number of U.S.-available findings for its triage and notification products to nine.
  • SYDNEY, April 12, 2023 /PRNewswire/ -- Annalise.ai, the global radiology AI company, announced today that it has received FDA 510(k) clearances covering an additional seven findings as part of the company's innovative AI-assisted triage and notification (CADt) solutions.
  • The clearances, including a suite of time-sensitive stroke findings and an expansion of findings for chest X-ray, build on Annalise's momentum and growth strategy in the U.S. market.

Lunit and Agfa Announce Lunit INSIGHT CXR's Integration in Agfa's MUSICA® Workstation; Demonstration and Presentation to be Showcased at ECR 2023

Retrieved on: 
Monday, February 27, 2023

SEOUL, South Korea, Feb. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) and Agfa Radiology Solutions today announced the integration of Lunit's AI solution for chest radiology, Lunit INSIGHT CXR, in the MUSICA® Workstation.

Key Points: 
  • SEOUL, South Korea, Feb. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) and Agfa Radiology Solutions today announced the integration of Lunit's AI solution for chest radiology, Lunit INSIGHT CXR, in the MUSICA® Workstation.
  • Agfa will showcase a demonstration of the integrated product at the upcoming European Congress of Radiology (ECR) 2023, to be held in Vienna, Austria, on March 1-5.
  • Lunit also announced that it will showcase a poster presentation highlighting Lunit INSIGHT CXR's ability to differentiate between normal and abnormal chest radiographs—one of 6 presentations Lunit will be delivering at ECR 2023.
  • Lunit will showcase a total of 6 abstracts at this year's ECR meeting, with 4 oral presentations and 2 poster presentations.

Lunit to Establish Subsidiary in Europe to Accelerate Business Expansion

Retrieved on: 
Friday, February 17, 2023

Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network across Europe and strengthen global capabilities

Key Points: 
  • Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network across Europe and strengthen global capabilities
    SEOUL, South Korea, Feb. 17, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer solutions, today announced its decision to establish a new subsidiary, Lunit Europe Holdings, following a board of directors meeting held on February 16.
  • While Lunit has previously managed its European business through its branch office, the establishment of Lunit Europe Holdings will lead the company's plans to expand its sales network in Europe and strengthen partnerships with global medical device companies.
  • Lunit Europe Holdings will be based in Amsterdam, the Netherlands, and is due to begin full-scale local recruitment.
  • With the formation of Lunit Europe Holdings, Lunit plans to expedite its business development across the European Union and the European Free Trade Association (EFTA).

Lunit to Establish Subsidiary in Europe to Accelerate Business Expansion

Retrieved on: 
Friday, February 17, 2023

Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network across Europe and strengthen global capabilities

Key Points: 
  • Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network across Europe and strengthen global capabilities
    SEOUL, South Korea, Feb. 17, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer solutions, today announced its decision to establish a new subsidiary, Lunit Europe Holdings, following a board of directors meeting held on February 16.
  • While Lunit has previously managed its European business through its branch office, the establishment of Lunit Europe Holdings will lead the company's plans to expand its sales network in Europe and strengthen partnerships with global medical device companies.
  • Lunit Europe Holdings will be based in Amsterdam, the Netherlands, and is due to begin full-scale local recruitment.
  • With the formation of Lunit Europe Holdings, Lunit plans to expedite its business development across the European Union and the European Free Trade Association (EFTA).

Cemtrex Completes Divestiture of Non-Core Assets to Focus on Accelerating Its Vicon and AIS Brands

Retrieved on: 
Tuesday, November 29, 2022

Brooklyn, NY, Nov. 29, 2022 (GLOBE NEWSWIRE) --  Cemtrex Inc. (NASDAQ: CETX, CETXP), a technology company driving innovation in Internet of Things (IoT), security, machine vision & artificial intelligence, and augmented & virtual reality, today announced that the Company has undertaken a transformative restructuring in which it has divested its Smartdesk and VR subsidiaries in order to focus exclusively on its Vicon Industries and Advanced Industrial Services (AIS) businesses. The restructuring is the culmination of Cemtrex’s previously announced strategic shift towards prioritizing its core businesses.

Key Points: 
  • We believe this shift in focus to capture significant near-term recurring revenue opportunities in Vicon will maximize shareholder value over the next several years.
  • For AIS, the company continues to be a strong source of cash flow with high repeat business and a well-known reputation.
  • As part of the strategic restructuring, on November 22, 2022, Cemtrex completed a divestiture of its Smartdesk, CXR services, Cemtrex Labs, Virtual Driver Interactive and Bravo Strong assets and trade liabilities, allowing Cemtrex to focus on the Vicon and AIS businesses.
  • With the divestments completed, we will be able to drive growth capital to Vicon and focus on a return to profitability.